STOCK TITAN

Salarius Pharmaceuticals Inc - SLRX STOCK NEWS

Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) is a clinical-stage biotechnology company pioneering targeted therapies for cancers with high unmet medical needs. This page serves as the definitive source for verified news and official updates, providing stakeholders with timely insights into the company's progress in oncology drug development.

Investors and researchers will find curated press releases covering clinical trial milestones, regulatory developments, and strategic partnerships. Key focus areas include updates on Salarius' protein degradation therapies and inhibitor candidates, financial disclosures, and collaborative research initiatives in precision medicine.

All content is rigorously sourced from SEC filings, corporate communications, and validated industry reports. The repository is maintained to support informed analysis while adhering to financial compliance standards. Bookmark this page for efficient tracking of SLRX's advancements in addressing gene dysregulation through innovative biopharmaceutical approaches.

Rhea-AI Summary

Salarius Pharmaceuticals (SLRX) announced a public offering of 14,614,541 shares at $1.3685 each, aiming to raise approximately $20 million, with closing expected around March 8, 2021. The offering includes a 45-day option for underwriters to purchase an additional 2,192,181 shares. Ladenburg Thalmann is the book-running manager for this offering. The proceeds will support Salarius's clinical programs, including trials for its lead candidate, seclidemstat, a potential treatment for pediatric cancers and solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.15%
Tags
-
Rhea-AI Summary

Salarius Pharmaceuticals (Nasdaq: SLRX) has announced the commencement of an underwritten public offering of its common stock. The offering is subject to market conditions, and details regarding its size and terms remain undetermined. Ladenburg Thalmann & Co. Inc. is the sole book-running manager for this offering. The company has a registered shelf statement with the SEC, allowing for the sale of shares. Salarius focuses on developing new cancer therapies, particularly for pediatric and other challenging cancers, with its lead candidate currently undergoing clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.15%
Tags
-
Rhea-AI Summary

Salarius Pharmaceuticals (Nasdaq: SLRX) has initiated the expansion stage of its Phase 1/2 clinical trial for seclidemstat, targeting relapsed and refractory Ewing sarcoma patients. This phase includes two arms: combining seclidemstat with topotecan and cyclophosphamide for Ewing sarcoma, and using it as a single-agent therapy for Ewing-related sarcomas. Preliminary results show extended time to progression, with data readouts expected by the end of 2021 into 2022. The company aims to enhance treatment options for patients with limited alternatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.36%
Tags
Rhea-AI Summary

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that CEO David Arthur will present at the Diamond Equity Research Emerging Growth Invitational Conference on February 24, 2021. The presentation will cover Salarius’ business overview, recent achievements, and upcoming clinical milestones for seclidemstat, a reversible LSD1 inhibitor currently in Phase 1/2 trials for Ewing sarcoma and advanced solid tumors. Attendees can participate in a Q&A session. A recording will be available post-event on the company’s investor page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.62%
Tags
conferences
-
Rhea-AI Summary

Salarius Pharmaceuticals has established the recommended Phase 2 dose (RP2D) for its seclidemstat in a Phase 1/2 trial focused on relapsed/refractory Ewing sarcoma. Data from the trial showcased a manageable safety profile and preliminary signs of drug activity, particularly in Ewing-related sarcoma patients. Encouraging results indicated over 75% tumor shrinkage in a refractory patient. The trial plans to expand to treat more patients and present full findings at a medical conference. Further data readouts are expected by the end of this year and early next year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
-
Rhea-AI Summary

Salarius Pharmaceuticals announced its participation in the BIO CEO & Investor Digital Conference from February 16 to February 18, 2021. The company's management will engage in one-on-one virtual meetings with investors to discuss business developments and milestones related to seclidemstat, a reversible LSD1 inhibitor in clinical trials for Ewing sarcoma and advanced solid tumors. Salarius has received multiple FDA designations for seclidemstat and financial backing for its clinical programs, emphasizing its commitment to innovative cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
conferences
Rhea-AI Summary

Salarius Pharmaceuticals (Nasdaq: SLRX) announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. The company focuses on developing innovative cancer therapies, particularly its lead candidate, seclidemstat, which is in clinical trials for pediatric cancers and advanced solid tumors. Salarius has received multiple designations from the FDA for seclidemstat and financial support from the National Pediatric Cancer Foundation and CPRIT to further its clinical programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
none
-
Rhea-AI Summary

Salarius Pharmaceuticals (Nasdaq: SLRX) announced that Dr. Daniela Y. Santiesteban will join the panel on Targeted Cancer Therapeutics at Noble Capital Markets’ 17th Annual Small & Microcap Investor Conference, taking place January 19-21, 2021, virtually. The discussion will focus on the status and future of targeted cancer therapies. Salarius is advancing its lead candidate, seclidemstat, a reversible LSD1 inhibitor, currently undergoing clinical trials for Ewing sarcoma and advanced solid tumors. The company aims to establish maximum tolerated dose in its ongoing trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
conferences
-
Rhea-AI Summary

Salarius Pharmaceuticals (Nasdaq: SLRX) announced a $0.9 million payment from the Cancer Prevention and Research Institute of Texas, part of a $1.7 million grant for its lead drug candidate, seclidemstat. This funding supports two clinical trials targeting Ewing sarcoma and advanced solid tumors. With a total of $4.8 million in remaining funds, Salarius is positioned to advance its clinical programs. The company has secured additional funding of $3.6 million from prior financing efforts, allowing it to progress through critical development milestones in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
none
Rhea-AI Summary

Salarius Pharmaceuticals is set to participate in the Biotech Showcase Digital and BIO @ JPM from January 11-15, 2021. This virtual participation coincides with the 39th Annual Healthcare Conference 2021. Salarius aims to discuss its clinical programs for seclidemstat, a potential treatment for Ewing sarcoma and other cancers. Key milestones include establishing maximum tolerated doses and advancing into the dose-expansion phase of trials. Salarius has received FDA designations for its lead candidate, focusing on pediatric and solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
conferences
Salarius Pharmaceuticals Inc

Nasdaq:SLRX

SLRX Rankings

SLRX Stock Data

1.17M
1.71M
2.1%
4.8%
5.41%
Biotechnology
Pharmaceutical Preparations
Link
United States
HOUSTON